Following the publication of this article , the authors requested to amend the characterisation of lanadelumab from humanised to the correct fully human. Therefore, the fourth paragraph under Recommendation #24 should be amended to read: Lanadelumab (Takeda), a fully human monoclonal antibody against kallikrein, takes approximately 70 days to reach a steady state concentration , and is therefore not recommended for STP Similarly, the first paragraph under Recommendation #27 should be amended to read: Lanadelumab is a subcutaneously injectable, fully human, anti-active plasma kallikrein monoclonal antibody (IgG1/K-light chain).
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
- Pulmonary and Respiratory Medicine